Clonmel Healthcare Ltd. Pharos Pharmaceutical Oriented Services Ltd. STADA Arzneimittel AG STADA Arzneimittel GmbH
PolandAll drugs from this manufacturer
-
The medicine is used to treat adults and children and adolescents suffering from Philadelphia chromosome-positive chronic myeloid leukemia (CML Ph+). It is intended for individuals with newly diagnosed disease or for those for whom previous treatment has ceased to be effective or has caused severe side effects.
Dosage form: capsules, hard
Active substance Dosage nilotinib 50 mg ATC: L01EA03
-
The medicine is used to treat Philadelphia chromosome-positive chronic myeloid leukemia (CML Ph+) in adults, as well as in children and adolescents with newly diagnosed disease or in patients for whom previous treatment has not been effective or has caused severe side effects.
Dosage form: capsules, hard
Active substance Dosage nilotinib 150 mg ATC: L01EA03
-
The medicine is used to treat Philadelphia chromosome-positive chronic myeloid leukemia (CML Ph+) in adults, as well as in children and adolescents with newly diagnosed disease or in patients for whom previous treatment has not been effective or has caused severe side effects.
Dosage form: capsules, hard
Active substance Dosage nilotinib 200 mg ATC: L01EA03